This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
- Pretargeted Radioimmunotherapy for B-Cell Lymphomas
- Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
- Residualizing Iodine Markedly Improved Tumor Targeting Using Bispecific Antibody-Based Pretargeting
- Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
- Reagents and Methods for PET Using Bispecific Antibody Pretargeting and 68Ga-Radiolabeled Bivalent Hapten-Peptide-Chelate Conjugates
- In Vivo Evaluation of Pretargeted 64Cu for Tumor Imaging and Therapy
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody
- Targeted Therapy of Cancer with Radiolabeled Antibodies
- Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
- A 3-Step Pretargeting Strategy to Image Infection
- Biodistribution and Dosimetry of Pretargeted Monoclonal Antibody 2D12.5 and Y-Janus-DOTA in BALB/c Mice with KHJJ Mouse Adenocarcinoma